Review: Clinical aspects of the management of HIV lipodystrophy
- 1 May 2008
- journal article
- Published by SAGE Publications in British Journal of Diabetes
- Vol. 8 (3) , 113-119
Abstract
Chronic complications of human immunodeficiency virus (HIV) and highly active retroviral therapy have become increasingly relevant as life expectancy for HIV patients has improved and the affected population ages. HIV-associated lipodystrophy syndrome is characterised by an abnormal fat distribution syndrome associated with metabolic disturbances including insulin resistance, and deranged glucose and lipid metabolism. It is associated with increased risks of progression to type 2 diabetes and cardiovascular disease. Lipodystrophy is a clinical diagnosis and mostly subjective as standardised diagnostic criteria have not yet been defined. Several therapeutic interventions have been investigated including lifestyle therapy, vitamin supplements, switching antiretroviral therapy and specific therapies for insulin resistance and hyperlipidaemia. Current management options for HIV associated lipodystrophy are limited and are mostly based on avoidance of risk factors and switching of antiretroviral drugs. Therapies to improve insulin resistance have been tried but they are frequently ineffective as are lipid-lowering drugs. Interest in anabolic agents has been resurrected and new clinical data suggest that HIV-associated lipodystrophy growth hormone releasing factor therapy may have a beneficial role in the treatment of HIV-associated lipodystrophy. However, there still remains a need for robust prospective cohort studies and well designed intervention trials to resolve the aetiology and define the best treatment for this complication of HIV disease and its treatment.Keywords
This publication has 74 references indexed in Scilit:
- HIV-associated lipodystrophy - a new metabolic syndromeBritish Journal of Diabetes, 2008
- Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort studyBMJ, 2007
- Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient PopulationClinical Infectious Diseases, 2007
- Heart positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemiaContemporary Clinical Trials, 2006
- Dyslipidaemia and cardiovascular risk in HIV infectionCurrent Medical Research and Opinion, 2005
- Small dense LDL and atherogenic lipid profile in HIV-positive adultsAIDS, 2003
- Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV InfectionClinical Pharmacokinetics, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with LipodystrophyClinical Infectious Diseases, 2000
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998